"At present, those interested in buying our patent are mostly overseas companies," says Hsu. A patent transfer remains in deliberation, mainly because the overseas companies must compare it with existing traditional vaccines.
「目前和我們接觸、有興趣買專利的多為國外公司，」徐堯煇指出，專利輸出仍在洽談中，原因是國外公司必須要與現有的傳統疫苗做比較。